GT Biopharma (NASDAQ:GTBP) Stock Price Down 8.8% – What’s Next?
by Mitch Edgeman · The Markets DailyGT Biopharma, Inc. (NASDAQ:GTBP – Get Free Report) shares fell 8.8% on Monday . The company traded as low as $0.3730 and last traded at $0.3877. Approximately 1,719,132 shares traded hands during trading, an increase of 45% from the average session volume of 1,181,820 shares. The stock had previously closed at $0.4250.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of GT Biopharma in a research note on Wednesday, July 8th. Wall Street Zen raised shares of GT Biopharma to a “hold” rating in a report on Saturday, June 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.
Get Our Latest Research Report on GT Biopharma
GT Biopharma Trading Down 8.8%
The firm has a market cap of $17.19 million, a price-to-earnings ratio of -0.06 and a beta of 0.84. The stock has a 50-day moving average of $0.43 and a 200-day moving average of $0.49.
GT Biopharma (NASDAQ:GTBP – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.03). As a group, research analysts expect that GT Biopharma, Inc. will post -0.34 earnings per share for the current fiscal year.
Institutional Trading of GT Biopharma
A hedge fund recently bought a new stake in GT Biopharma stock. Everhart Financial Group Inc. acquired a new stake in GT Biopharma, Inc. (NASDAQ:GTBP – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 100,000 shares of the company’s stock, valued at approximately $49,000. Everhart Financial Group Inc. owned about 0.23% of GT Biopharma as of its most recent SEC filing. 8.15% of the stock is currently owned by institutional investors and hedge funds.
GT Biopharma Company Profile
GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.
The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).